COVID-19: Vaccines and Therapeutics
The AHA has launched a new webpage that houses AHA-developed tools, as well as resources from the federal government and other stakeholders related to a COVID-19 vaccine.
This webpage is intended to help keep the field informed of important updates related to vaccine development, distribution, utilization protocols, supply chain and many other issues, through AHA-developed tools, as well as resources from the federal government and other stakeholders.
AHA comments on the National Academies of Sciences, Engineering and Medicine’s Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine.
The AHA urged the National Academies of Sciences, Engineering and Medicine to adopt a unified set of guidelines to account for the variables associated with all issues of the eventual allocation of COVID-19 vaccine allocation.
The National Academies of Sciences, Engineering, and Medicine today released for public comment a discussion draft of a preliminary framework to assist policymakers in planning for equitable allocation of a vaccine against COVID-19.
Download this infographic to learn how the AHA is working to make sure hospitals and health systems on the front lines have the supplies and equipment they need.
McKesson Corporation will serve as a central distributor of future COVID-19 vaccines and related supplies, the departments of Health and Human Services and Defense announced.
The departments of Health and Human Services and Defense will pay Moderna Inc. about $1.5 billion to produce and deliver 100 million doses of its COVID-19 vaccine candidate to vaccinate Americans if authorized by the Food and Drug Administration, the agencies announced.
The departments of Health and Human Services and Defense will pay Janssen Pharmaceutical Companies of Johnson & Johnson $1 billion to manufacture 100 million doses of its COVID-19 vaccine candidate for use in clinical trials, or to vaccinate Americans if authorized by the Food and Drug…
The Department of Health and Human Services announced that it will partner with the Department of Defense to fund the advanced development — including clinical trials and large-scale manufacturing — of a COVID-19 investigational vaccine from Sanofi and GlaxoSmithKline.